Forskning ved Københavns Universitet - Københavns Universitet

Forside

The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment. / Kloppenborg, Julie T.; Gamborg, Michael; Fonvig, Cilius E.; Nielsen, Tenna R.H.; Pedersen, Oluf; Johannesen, Jesper; Hansen, Torben; Holm, Jens-Christian.

I: Pediatric Diabetes, Bind 19, Nr. 3, 2018, s. 366-374.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Kloppenborg, JT, Gamborg, M, Fonvig, CE, Nielsen, TRH, Pedersen, O, Johannesen, J, Hansen, T & Holm, J-C 2018, 'The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment', Pediatric Diabetes, bind 19, nr. 3, s. 366-374. https://doi.org/10.1111/pedi.12605

APA

Kloppenborg, J. T., Gamborg, M., Fonvig, C. E., Nielsen, T. R. H., Pedersen, O., Johannesen, J., ... Holm, J-C. (2018). The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment. Pediatric Diabetes, 19(3), 366-374. https://doi.org/10.1111/pedi.12605

Vancouver

Kloppenborg JT, Gamborg M, Fonvig CE, Nielsen TRH, Pedersen O, Johannesen J o.a. The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment. Pediatric Diabetes. 2018;19(3):366-374. https://doi.org/10.1111/pedi.12605

Author

Kloppenborg, Julie T. ; Gamborg, Michael ; Fonvig, Cilius E. ; Nielsen, Tenna R.H. ; Pedersen, Oluf ; Johannesen, Jesper ; Hansen, Torben ; Holm, Jens-Christian. / The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment. I: Pediatric Diabetes. 2018 ; Bind 19, Nr. 3. s. 366-374.

Bibtex

@article{0ed2f446e7c345458b49ae74d7a3195a,
title = "The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment",
abstract = "OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.",
keywords = "Journal Article, Body Mass Index, Glucose Intolerance/blood, Humans, Insulin/blood, Blood Glucose, Male, Prediabetic State/blood, Pediatric Obesity/blood, Young Adult, Weight Loss, Adolescent, Female, Glycated Hemoglobin A/metabolism, C-Peptide/blood, Weight Reduction Programs/statistics & numerical data, Child, Longitudinal Studies, prediabetes, weight loss, children, impaired glucose metabolism, obesity",
author = "Kloppenborg, {Julie T.} and Michael Gamborg and Fonvig, {Cilius E.} and Nielsen, {Tenna R.H.} and Oluf Pedersen and Jesper Johannesen and Torben Hansen and Jens-Christian Holm",
note = "Funding information The Novo Nordisk Foundation, Grant/Award number: NNF15OC0016544; Novo Nordisk, Grant/Award number: unrestricted educational grant; The Danish Innovation Foundation, Grant/Award number: 0603‐00457B; The Region Zealand Health Scientifics Research Foundation",
year = "2018",
doi = "10.1111/pedi.12605",
language = "English",
volume = "19",
pages = "366--374",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment

AU - Kloppenborg, Julie T.

AU - Gamborg, Michael

AU - Fonvig, Cilius E.

AU - Nielsen, Tenna R.H.

AU - Pedersen, Oluf

AU - Johannesen, Jesper

AU - Hansen, Torben

AU - Holm, Jens-Christian

N1 - Funding information The Novo Nordisk Foundation, Grant/Award number: NNF15OC0016544; Novo Nordisk, Grant/Award number: unrestricted educational grant; The Danish Innovation Foundation, Grant/Award number: 0603‐00457B; The Region Zealand Health Scientifics Research Foundation

PY - 2018

Y1 - 2018

N2 - OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.

AB - OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.

KW - Journal Article

KW - Body Mass Index

KW - Glucose Intolerance/blood

KW - Humans

KW - Insulin/blood

KW - Blood Glucose

KW - Male

KW - Prediabetic State/blood

KW - Pediatric Obesity/blood

KW - Young Adult

KW - Weight Loss

KW - Adolescent

KW - Female

KW - Glycated Hemoglobin A/metabolism

KW - C-Peptide/blood

KW - Weight Reduction Programs/statistics & numerical data

KW - Child

KW - Longitudinal Studies

KW - prediabetes

KW - weight loss

KW - children

KW - impaired glucose metabolism

KW - obesity

U2 - 10.1111/pedi.12605

DO - 10.1111/pedi.12605

M3 - Journal article

C2 - 29159854

VL - 19

SP - 366

EP - 374

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 3

ER -

ID: 189863928